HUE032074T2 - Aktív, nagymértékben foszforilált, emberi liszoszomális szulfatáz enzimek elõállítása és alkalmazása - Google Patents

Aktív, nagymértékben foszforilált, emberi liszoszomális szulfatáz enzimek elõállítása és alkalmazása Download PDF

Info

Publication number
HUE032074T2
HUE032074T2 HUE09702074A HUE09702074A HUE032074T2 HU E032074 T2 HUE032074 T2 HU E032074T2 HU E09702074 A HUE09702074 A HU E09702074A HU E09702074 A HUE09702074 A HU E09702074A HU E032074 T2 HUE032074 T2 HU E032074T2
Authority
HU
Hungary
Prior art keywords
galns
enzyme
lake
sulfatase
lysosomal
Prior art date
Application number
HUE09702074A
Other languages
English (en)
Inventor
Michel Claude Vellard
Vish Koppaka
Melita Dvorak-Ewell
Erno Pungor
Charles Hague
Original Assignee
Biomarin Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40451345&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE032074(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biomarin Pharm Inc filed Critical Biomarin Pharm Inc
Publication of HUE032074T2 publication Critical patent/HUE032074T2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06001—Arylsulfatase (3.1.6.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/44—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving esterase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06004—N-Acetylgalactosamine-6-sulfatase (3.1.6.4)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06014—N-Acetylglucosamine-6-sulfatase (3.1.6.14)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/924—Hydrolases (3) acting on glycosyl compounds (3.2)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G01N2400/10—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • G01N2400/38—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence, e.g. gluco- or galactomannans, e.g. Konjac gum, Locust bean gum, Guar gum
    • G01N2400/40—Glycosaminoglycans, i.e. GAG or mucopolysaccharides, e.g. chondroitin sulfate, dermatan sulfate, hyaluronic acid, heparin, heparan sulfate, and related sulfated polysaccharides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)

Claims (2)

  1. :jK' tó w J4: >A. ® </ :¾ tó » a; ,0 :--- 1 :cr tó 'sr « &amp; -¾- » F £ « :¾. rs :¾¾. -m ·»' J&amp;: tó £ ö E: 2. B ::·:· ·.·:> :cp g X .2- *" p :'-· Z '< ss g ^ /- ' r :0. F ... 3$: F .2. b .¾ '* .*-· < s*v’ -¾ n ·«' .«: / 3Î:; 2: 'S: rí tó F ~ B' F § ·4 X F X Ρ 7 tó :F % y 2. ~ I- I F ::: s W * I F g* 11 » 2 « 1 a Î t I ft ï Ä s ! Ä e ! a I a 111 “ 1111 g I i ï ï t ï s r « - s ? ï ? 11 ; ï « s t “ I * f ; I f j: ϊ s &amp; s :?r B /-. %· .m fy- '?' -¾ 3S. .tó tó: $;· .#* ¢0: .·£*· '*% '£ζ £ £ <S; íf g ^ tó % > 3$ IS tó ά· Ψ Μ·· — 1 ^ ^ -5’ Ε ^ w ^ tó' .f: -F ^ ti ;gf E :< Ε I i i 1 I # I I f § I f I I I ** I s p f f t i I I I 1 I ^ I i * % -¾ f. ij :¾ % % Ê 7 f % f B :f :¾ 1: f -¾ ír % s Ç f |- s. P: 1 f. f ^ ^ :-¾ S &amp; % 7 2· :V: - g -- c -· S f > f p. > 4 :¾ f ψ .¾ $ § £ t Í7 B g S 7: t % 11 t ï - I ! ! * i I f i 1 I i I < :l 11 ® ï % I &amp; % 1: I § : o. ..,: ^ :¾. -cr &amp; &amp; f' S Ψ W % -¾ - ^ » S: .¾ :-. B;, g ™ w M ^ S' '0 fe: -,«k *s: S' %' s íí :»: ®t- fer- »: * á- ^i: ««, λ ·»;. :¾ y· .ar ·»*· xs: ,. ~i N< ?*. » g- B: fe s a b k r-, s, ·ί~> s« ^ «· m % # # s h g. s ·<» .-¾ :®. 2 g s »*,. ^ rr έ 2. ~ a: s; s p' s u ’< p- s 2, -=· 7; 7: &amp; ψ Sr » ^ s -:.:.·· «· -¾ S' "B g- P S- ·-<' S » S-, ψ. A, » ψ \j :S. .-4 S; £. ,;· ':... P ™ «; jx; — v :» œ; **j- Ψ- '<&amp;. >p. S'- a -Á a p P P: 0 0 -<&amp; g- Pi § :-- -7 44 g·- Pi 4S <2 -» £3 s :¾¾ W ss: s- S' -¾ ;g f P I- fi b f S s :1 c: # § ό € Ψ :g 0 g g § > 1 |- gf p B' P' -¾ S ·,·-· Ä S :Px g — £ w S > S > PS: S: S. B- 2- '-0. g ai ÿ? ír,: ^- s; f :: # I I ..ο p % s' % g· ' i. > 7 1: ρ 1- :1- ,i p f I f i |l f s Ê &amp; â c g 5- :p *' i. p g. 7 % Ú B % Ű > % W 1 § S P &amp; ** | S ^ I -I I f ;f p 1 1' i :ä I > f 1 E I |: 1, :I 1 S 1 à p 4 1 I p: p ρ % s, 1 m £ v"? ρ á © -à i :p '« w g- g P .«§ -s ». £ 0 % %. χ· B g % ρ I S: f f I tó 2 S £ S 5- Έ. f :¾ !' a 1 a $ € p :| p a s r tó g. É: S: B: g: '«' # g ®; tó £. f; gg S- B % S ·-" S .» p g: U U m W &amp; X- f%· p tó « a r: s g «" g- 8 g- a a g: rs ^ g £ x .«..: τ~ g- ^ <· g :fc tó i f i 11 ! 11 I I 11 I I ï 11 f S ï 11 S I « i Ä S. B tó ;» Ê 'g s. % % % Mi -P P % M é :¾ tó $ P, % % i. % '% tó: P » ψ· s. t i P a f i f t " 1 ;r” i f I f i f f I I f I f ;; I 1 1 r: I I tó :| .t .# f I I- s -? % 2 z. I « tó |: S- g % ψ -g f .tó f s I t tó tó f: L I. t £ £ - ? # - tó f I &amp; a P s i :,g i f r 2. :o :<: 1 %. I f; f r tó tó L· tó tó tó tó P - | g .tó g. S | tó t 1: # tó I-: ' I tó tó 7; tó tó tó tó :g § |. t F 1 f | 51 I tó m M :fe =S tó tó > > tó I: tó: tó i: 1' g f * g ™ f :i, &amp; | :g a ' F tó ρ· n F T » £ F P5 tó gí tó Ä Ví .8: Í4- tó > w: tó tó F' S' -·: :S tó tó tó f" g F tó P S" ,.,. S-: 7: :f g. S tó ;i: 1 S- < P - P r F S g i tó I: tó F I I tó > I i f a f % í i « B t S I I ï S II « P ï f- 3 $ f t 3: 3 :® # a Ρ « a # g- s i. VÍC :gjÿ tó* s; C :F' v>; -ÖSs ^ ^ ^ XI ^ ’<: F g iá ® p ' ' tó B -tó: S ® :» tó ä é -í*i· 8 í * 1 I 1- I I: s S i 1 J I Ï 8: f i € * Ç f Ψ í if S. s s: i * I ? I r I = 50. A ?. igénypont szerinti készítmény az oit meghatározott alkalmazásra vagy a 8. igéttypom szerlnu alkalmazás. ahol a CiALMS enzim redukáló körolmények között vág»«» SOS·· F A GO. voran Coenumie Slue îVÿ-· ’|5:S^ifíl0i|;:í>íí^í!i^i^ ϊΐ·ίI, έί:«>όϊ>ί·;;?ί-:lá.íMií;íí proteinek. legalább 90Η-3 ||||||||||||||||, j!!Í:'''::|||||Í. t. î. kés/.itmény nz ctt :^:::^ÎÎ;^-iiiiiiiiii^ !!l eiéoypomok bálibbΙΑ:5í ΐίΐ5¾¾ iíH|||.:GÁl:iP:S ehzlm IBIpil^ií&amp;íáíjSít levő tisztein legalább Am ä Cso-fotmilgilcmne (FCUy) kö|yéÍÍtíl 1:2; A 7-50, igénypontok bármelyike szerint! készítmény az. ott megbatározott alkalmazásra vagy ah-ltl igénypontok-bármelyike szerinti alkalmazás, ahol a GAIMS enzim S3, pozickiíabtt« íévö -tisztem J.egaí-áb.b.-9Uk«* á.Cö-íomulgHcinné (FQIy) -konvertált:.· 13. A 7-12. igénypontok bármelyike szerinti készítmény az-ott meghatározott .alkat ntázásra vagy a 1M2. Igénypontok bánttciyíke szerinti alkalmam, ahol a kezeié?; hatásosságát az MÍ>.S iVavban vagy .Montul» A szindróntában szenvedd alanyban a ksratán-szatiat vizelettel-tÖrténiVkiválasZtáaán&amp;k mérésével határozzak öreg. aha! a* MFS IVa-ban vagy Morcom Ä szbidmmábast szenvedő alany vizeleten mért KS-sxntbéi ittíroíál alany vízek'tben mert ΗΛ .-cmtH'rtd e* vagy MFh. iVa-ban vagy Morquio A szindrómába» -szenvedő, kezeletlen alany vizeletben'»}«« K^szmíjéval vagy a« azonos alany GALMS~enzimnse|:.td«éná-lctÍzeiéat megeJ&amp;riie« a vizeletben mén KS-srJntjévcl hasonlítjuk össze, vagy ahoi a kezelés hatásosságát az alany fttnkekmáíis vizsgálatával tárástesztekkel, lépcsőzéssé! mért állóképesség vagy polmonáliaAesptratorifcua funkció alapján határozzuk meg, ahol adok esetben a járásieszt « 6'vágy ' 12 'pere alatt sétál· 'távolságot ntéo ystgyl!! :$hb:|:Í;$á^ .pöSpilliält: meglesi lépcsők s/asnüt méri vagy ahol a puimonáii.Vre-piratorrki.i!·: inrskdot korökhis funkció íeehokardmcram} vagy putmanálss fenkció íl'VC, FFV llkhiy «íiííiíSa^^mléiä|S|íiíáís M. A 13. igénypont szerinti készítmény az ott meghatározott alkalmazásra. vagy tt 1:1 igénypont szentül alkalmazás, ahol GAUNS-enzimtuel történő kezelést követően a vizeletben mért KS csökkenése nagyobb, miot 201(, vagy ahol tiALNS-enstmmel történő kezdést követően a vizeletben mert KS csökkenése nagyobb, mint lil!
  2. 15, Az t-<S, igénypontok bármelyike szerinti O A LNS^eîtzimkészJîtnény. a 7-14. igénypontok bármelyike szerinti készítmény az ott meghatározót} alkalmazásra vagy a l-M. igénypontok bármelyike szét inti alkalmazás, ahol a sebes irányítószígnái tartalmaz, osont iíáavlrópeptidei.
HUE09702074A 2008-01-18 2009-01-16 Aktív, nagymértékben foszforilált, emberi liszoszomális szulfatáz enzimek elõállítása és alkalmazása HUE032074T2 (hu)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2217908P 2008-01-18 2008-01-18
US9937308P 2008-09-23 2008-09-23
US11024608P 2008-10-31 2008-10-31

Publications (1)

Publication Number Publication Date
HUE032074T2 true HUE032074T2 (hu) 2017-08-28

Family

ID=40451345

Family Applications (2)

Application Number Title Priority Date Filing Date
HUE09702074A HUE032074T2 (hu) 2008-01-18 2009-01-16 Aktív, nagymértékben foszforilált, emberi liszoszomális szulfatáz enzimek elõállítása és alkalmazása
HUS1700022C HUS1700022I1 (hu) 2008-01-18 2017-05-18 Aktív, nagymértékben foszforilált, emberi liszoszomális szulfatáz enzimek elõállítása és alkalmazása

Family Applications After (1)

Application Number Title Priority Date Filing Date
HUS1700022C HUS1700022I1 (hu) 2008-01-18 2017-05-18 Aktív, nagymértékben foszforilált, emberi liszoszomális szulfatáz enzimek elõállítása és alkalmazása

Country Status (28)

Country Link
US (7) US8128925B2 (hu)
EP (2) EP3219795B1 (hu)
JP (1) JP5687069B2 (hu)
KR (1) KR101744142B1 (hu)
CN (2) CN102027110A (hu)
AR (1) AR070198A1 (hu)
AU (1) AU2009205978B2 (hu)
BR (1) BRPI0906948B1 (hu)
CA (2) CA2711590C (hu)
CL (1) CL2009000091A1 (hu)
CY (2) CY1118984T1 (hu)
DK (1) DK2245145T3 (hu)
HK (1) HK1244505A1 (hu)
HR (1) HRP20170366T1 (hu)
HU (2) HUE032074T2 (hu)
IL (1) IL206975A (hu)
LT (2) LT2245145T (hu)
MX (1) MX2010007846A (hu)
NL (1) NL300874I2 (hu)
NO (1) NO2017024I1 (hu)
PE (2) PE20091319A1 (hu)
PL (1) PL2245145T3 (hu)
PT (1) PT2245145T (hu)
RU (1) RU2510820C2 (hu)
SI (1) SI2245145T1 (hu)
TW (1) TWI395816B (hu)
WO (1) WO2009091994A2 (hu)
ZA (1) ZA201004674B (hu)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104480140B (zh) 2007-04-03 2019-12-31 奥克西雷恩英国有限公司 分子的糖基化
CN102027110A (zh) * 2008-01-18 2011-04-20 生物马林药物股份有限公司 制备活性高度磷酸化人溶酶体硫酸酯酶及其应用
CN104651428A (zh) 2009-09-29 2015-05-27 根特大学 水解甘露糖-1-磷酸-6-甘露糖连接为磷酸-6-甘露糖
BR112012011980A2 (pt) 2009-11-19 2021-09-08 Oxyrane Uk Limited Métodos de produzir células transformadas de yarrowia lipolytica e proteínas-alvocompreendendo n-glicanos, células transformadas de yarrowia lipolytica e suas culturas, bem como composição compreendendo glicoproteínas
AR082319A1 (es) 2010-07-22 2012-11-28 Biomarin Pharm Inc Produccion de una n-acetilgalactosamina-6-sulfatasa humana activa altamente fosforilada y sus usos
US9689015B2 (en) 2010-09-29 2017-06-27 Oxyrane Uk Limited De-mannosylation of phosphorylated N-glycans
CN103328646B (zh) 2010-09-29 2021-06-18 奥克西雷恩英国有限公司 能够使甘露糖-1-磷酸-6-甘露糖连接脱帽并使磷酸化的n-聚糖脱甘露糖基化的甘露糖苷酶及促进糖蛋白的哺乳动物细胞摄取的方法
WO2012063984A1 (ko) * 2010-11-12 2012-05-18 주식회사 녹십자 개량형 이듀로네이트-2-설파타제 및 이의 용도
AU2010366066B2 (en) * 2010-12-22 2016-01-14 Fondazione Telethon Therapeutic strategies to treat CNS pathology in mucopolysaccharidoses
TW201307563A (zh) 2011-05-19 2013-02-16 Shire Human Genetic Therapies 純化乙醯肝素－ｎ－硫酸酯酶之方法
US20160145589A1 (en) 2011-06-24 2016-05-26 Green Cross Corporation Composition and formulation comprising recombinant human iduronate-2-sulfatase and preparation method thereof
US9249399B2 (en) 2012-03-15 2016-02-02 Oxyrane Uk Limited Methods and materials for treatment of pompe's disease
WO2013148323A1 (en) * 2012-03-30 2013-10-03 Shire Human Genetic Therapies Methods of analyzing and preparing protein compositions
US9150841B2 (en) 2012-06-29 2015-10-06 Shire Human Genetic Therapies, Inc. Cells for producing recombinant iduronate-2-sulfatase
US20140004097A1 (en) * 2012-06-29 2014-01-02 Shire Human Genetic Therapies, Inc. Method of producing recombinant iduronate-2-sulfatase
KR101380740B1 (ko) * 2012-06-29 2014-04-11 쉐어 휴먼 제네텍 세러피스, 인코포레이티드 이듀로네이트-2-설파타제의 정제
WO2014075688A1 (en) * 2012-11-13 2014-05-22 Ace Biosciences A/S PURIFICATION OF RECOMBINANT HUMAN GALACTOCEREBROSIDE β-GALACTOSIDASE (rhGALC)
WO2014136065A2 (en) * 2013-03-05 2014-09-12 Oxyrane Uk Limited Production of catalytically active type i sulfatase
JP6684715B2 (ja) * 2014-02-18 2020-04-22 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド リソソーム酵素のための基質クリアランスアッセイ
PT2970413T (pt) * 2014-04-01 2018-10-23 Swedish Orphan Biovitrum Ab Publ Sulfamidase modificada e sua produção
EP3101125A1 (en) * 2015-06-05 2016-12-07 Laboratorios Del Dr. Esteve, S.A. Adenoassociated virus vectors for the treatment of mucopolysaccharidoses
MX2018005258A (es) 2015-11-06 2019-09-04 Biomarin Pharm Inc Ensayos basados en células para la detección de anticuerpos u otros factores que neutralizan la absorción de enzimas lisosómicas.
RU2673038C2 (ru) * 2016-01-18 2018-11-21 ООО "Международный Биотехнологический Центр "Генериум" Лекарственное средство на основе бифункционального антитела для лечения мукополисахаридоза II типа
JP6430980B2 (ja) * 2016-03-09 2018-11-28 フォンダッツィオーネ・テレソン ムコ多糖症におけるｃｎｓ病変を処置するための治療戦略
WO2019045149A1 (en) 2017-08-31 2019-03-07 Green Cross Corporation PROCESS FOR PURIFYING SULFATASE PROTEIN
MA50746A (fr) 2017-10-02 2020-08-12 Denali Therapeutics Inc Protéines de fusion comprenant des enzymes d'enzymothérapie substitutive
EP3963073A4 (en) * 2019-04-29 2023-01-25 The University of North Carolina at Chapel Hill OPTIMIZED SUMF1 GENES AND EXPRESSION CASSETTE AND THEIR USE
RU2763990C2 (ru) * 2020-02-19 2022-01-12 Акционерное общество "ГЕНЕРИУМ" Клетка, продуцирующая с высокой эффективностью активный белок арилсульфатазу в, и способ получения этой клетки
MX2023004335A (es) 2020-10-14 2023-05-04 Denali Therapeutics Inc Proteinas de fusion que comprenden enzimas sulfoglucosamina sulfohidrolasa y metodos de estas.
KR20240045299A (ko) * 2021-08-18 2024-04-05 조인트-스톡 컴퍼니 "제네리움" 치료 효소의 표적화 전달

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4394448A (en) 1978-02-24 1983-07-19 Szoka Jr Francis C Method of inserting DNA into living cells
US4391904A (en) 1979-12-26 1983-07-05 Syva Company Test strip kits in immunoassays and compositions therein
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US5186941A (en) 1983-05-06 1993-02-16 Vestar, Inc. Vesicle formulation for the controlled release of therapeutic agents
US6048729A (en) 1987-05-01 2000-04-11 Transkaryotic Therapies, Inc. In vivo protein production and delivery system for gene therapy
PT101031B (pt) 1991-11-05 2002-07-31 Transkaryotic Therapies Inc Processo para o fornecimento de proteinas por terapia genetica
US6063630A (en) 1991-11-05 2000-05-16 Transkaryotic Therapies, Inc. Targeted introduction of DNA into primary or secondary cells and their use for gene therapy
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US7083793B2 (en) 1999-02-26 2006-08-01 Millennium Pharmaceuticals, Inc. Tango 243 polypeptides and uses thereof
US6537785B1 (en) 1999-09-14 2003-03-25 Genzyme Glycobiology Research Institute, Inc. Methods of treating lysosomal storage diseases
US6972124B2 (en) 2000-05-01 2005-12-06 Biomarin Pharmaceuticals Inc. Precursor of N-acetylgalactosamine-4-sulfatase, methods of treatment using said enzyme and methods for producing and purifying said enzyme
EP1395669B1 (en) 2001-01-26 2009-07-22 Selexis S.A. Matrix attachment regions and methods for use thereof
US20030040095A1 (en) * 2001-03-16 2003-02-27 Achille Arini Method for the production of pharmaceutically active recombinant proteins
AUPS293002A0 (en) 2002-06-14 2002-07-04 Women's And Children's Hospital Identification of oligosaccharides and their use in the diagnosis and evaluation of mucopolysaccharidoses and other related disorders
ES2566641T3 (es) * 2003-02-11 2016-04-14 Shire Human Genetic Therapies, Inc. Células que co-expresan una enzima que genera a una sulfatasa y una C-formiliglicina y sus métodos y usos
CA2554883C (en) * 2004-01-30 2013-10-01 Zymenex A/S Production and purification of recombinant arylsulfatase a
WO2005077093A2 (en) 2004-02-06 2005-08-25 Biomarin Pharmaceutical Inc. Manufacture of highly phosphorylated lysosomal enzymes and uses thereof
WO2005113765A2 (en) * 2004-05-06 2005-12-01 Biomarin Pharmaceutical Inc. Methods of activation of sulfatases and methods and compositions of using the same
US7863238B2 (en) 2004-06-10 2011-01-04 Saint Louis University Proteins with an attached short peptide of acidic amino acids
CA2607133A1 (en) 2005-05-02 2006-11-09 Toray Industries, Inc. Composition and method for diagnosing esophageal cancer and metastasis of esophageal cancer
EP1818395A1 (en) 2006-02-08 2007-08-15 Diatos Compositions and methods for treating lysosomal storage diseases
AU2008205410B2 (en) * 2007-01-05 2013-10-10 Massachusetts Institute Of Technology Compositions of and methods of using sulfatases from flavobacterium heparinum
WO2009034159A1 (en) 2007-09-12 2009-03-19 Vivendy Therapeutics Ltd: Short polypeptide mediated conformational changes promoting enhancement of enzymatic activity
US7722865B2 (en) * 2008-01-18 2010-05-25 Biomarin Pharmaceutical Inc. Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof
CN102027110A (zh) * 2008-01-18 2011-04-20 生物马林药物股份有限公司 制备活性高度磷酸化人溶酶体硫酸酯酶及其应用
AR082319A1 (es) * 2010-07-22 2012-11-28 Biomarin Pharm Inc Produccion de una n-acetilgalactosamina-6-sulfatasa humana activa altamente fosforilada y sus usos

Also Published As

Publication number Publication date
CA3112632A1 (en) 2009-07-23
CL2009000091A1 (es) 2009-03-27
DK2245145T3 (en) 2017-03-20
IL206975A (en) 2013-06-27
BRPI0906948A2 (pt) 2015-07-14
LTPA2017016I1 (lt) 2017-06-12
EP3219795A1 (en) 2017-09-20
PE20091319A1 (es) 2009-09-23
PT2245145T (pt) 2017-03-14
US20180208913A1 (en) 2018-07-26
PE20140841A1 (es) 2014-08-03
WO2009091994A2 (en) 2009-07-23
US8128925B2 (en) 2012-03-06
JP5687069B2 (ja) 2015-03-18
RU2510820C2 (ru) 2014-04-10
IL206975A0 (en) 2010-12-30
AR070198A1 (es) 2010-03-17
CY1118984T1 (el) 2017-11-14
US20090186011A1 (en) 2009-07-23
TWI395816B (zh) 2013-05-11
WO2009091994A3 (en) 2009-10-29
ZA201004674B (en) 2011-09-28
MX2010007846A (es) 2010-10-05
US9200264B2 (en) 2015-12-01
PL2245145T3 (pl) 2017-07-31
CA2711590C (en) 2021-03-23
WO2009091994A9 (en) 2009-12-03
BRPI0906948B1 (pt) 2023-05-16
US20200181590A1 (en) 2020-06-11
LTC2245145I2 (lt) 2019-04-25
LT2245145T (lt) 2017-04-10
US10934534B2 (en) 2021-03-02
KR101744142B1 (ko) 2017-06-07
US9873867B2 (en) 2018-01-23
US8420368B2 (en) 2013-04-16
CA2711590A1 (en) 2009-07-23
US20120208221A1 (en) 2012-08-16
AU2009205978A1 (en) 2009-07-23
KR20100108438A (ko) 2010-10-06
US20130236921A1 (en) 2013-09-12
HRP20170366T1 (hr) 2017-05-05
CN105274072A (zh) 2016-01-27
EP2245145B1 (en) 2016-12-14
SI2245145T1 (sl) 2017-05-31
NL300874I2 (nl) 2018-04-12
HUS1700022I1 (hu) 2017-06-28
US10563183B2 (en) 2020-02-18
CY2017018I2 (el) 2017-11-14
TW200934869A (en) 2009-08-16
CY2017018I1 (el) 2017-11-14
JP2011509674A (ja) 2011-03-31
AU2009205978B2 (en) 2014-04-10
EP2245145A2 (en) 2010-11-03
RU2010134412A (ru) 2012-02-27
US20160201039A1 (en) 2016-07-14
NO2017024I1 (no) 2017-05-30
CN102027110A (zh) 2011-04-20
US20210189357A1 (en) 2021-06-24
HK1244505A1 (zh) 2018-08-10
EP3219795B1 (en) 2024-03-13

Similar Documents

Publication Publication Date Title
US10934534B2 (en) Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof
US9567572B2 (en) Manufacture of active highly phosphorylated human N-acetylgalactosamine-6-sulfatase and uses thereof
US7722865B2 (en) Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof